G-CSF- and erythropoietin-based cell therapy: A promising strategy for angiomyogenesis in myocardial infarction

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 5, 2008, Pages 703-713

  Kang, Hyun Jae ^a   Kim, Hyo Soo ^a  

^a Seoul National University   (South Korea)

Author keywords

Angiogenesis; Erythropoietin; G CSF; Myocardial infarction; Stem cell

Indexed keywords

ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; ERYTHROPOIETIN; ERYTHROPOIETIN DERIVATIVE; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JANUS KINASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; RAPAMYCIN; STAT PROTEIN; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ANGINA PECTORIS; ANGIOGENESIS; ARTERY INTIMA PROLIFERATION; BLOOD VISCOSITY; BOLUS INJECTION; CANCER GROWTH; CELL COUNT; CELL DIFFERENTIATION; CELL FUNCTION; CELL HOMING; CELL LINEAGE; CELL PROLIFERATION; CELL PROTECTION; CLINICAL TRIAL; COLONY FORMING CELL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BLOOD FLOW; CORONARY STENT; DRUG EFFECT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HEART ARRHYTHMIA; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MESENCHYMAL STEM CELL; MONOTHERAPY; NONHUMAN; PARACRINE SIGNALING; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; THROMBOSIS; TREATMENT DURATION; ANIMAL; BIOLOGICAL THERAPY; DISEASE MODEL; HEART VENTRICLE REMODELING; HOSPITALIZATION; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGENERATION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; REGENERATION; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TISSUE THERAPY; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 47149091118     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.5.703     Document Type: Review

References (104)

1. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infracted myocardium. Nature 410, 701-705 (2001).
2. Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7, 430-436 (2001).
3. Orlic D, Kajstura J, Chimenti S et al. Mobilized bone marrow cells repair the infracted heart, improving function and survival. Proc. Natl Acad Sc. USA 98, 10344-10349 (2001).
4. Hill JM, Syed MA, Arai AE et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J. Am. Coll. Cardiol. 46(9), 1643-1648 (2005).
5. Kawada H, Fujita. J, Kinjo K et al Nonhematopoictic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 104, 3581-1587 (2004).
6. Ripa RS, Haack-Sorensen M, Wang Y et al. Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the Stem Cells in Myocardial Infarction (STEMMI) trial. Circulation 116, I-24-I-30 (2007).
7. Sato T, Suzuki H, Kusuyama T et al. G-CSF after myocardial infarction accelerates angiogenesis and reduces fibrosis in swine. Int. J. Cardiol. DOI: 17692407 (2007) (Epub ahead of print).
8. Ohtsuka M, Takano H, Zou Y et al. Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J 18, 851-853 (2004)
9. Balsam LB, Wagers AJ, Christensen JL et al. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428, 668-673 (2004).
10. Murry CE, Soonpaa MH, Reinecke H et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428, 664-668 (2004).
11. Powell TM, Paul JD, Hill JM et al. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cell in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 25(2) 296-301 (2005).
12. Honold J, Lehmann R, Heeschen C et al Effects of granulocyte colony simulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 26(10), 2238-2243 (2006).
13. Britten MB, Abohnaali ND, Assmus B et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 108, 2212-2218 (2003).
14. Heeschen C, Lehmann R, Honold J et al. Profoundly reduced neovascularization capacity of bone marrow mononudear cells derived from patients with chronic ischemic heart disease. Circulation 109, 1615-1622 (2004).
15. Assmus B, Urbich C, Aicher A et al. HMG-CoA reductase inlubitors reduce senescence and increase proliferation of endothetial progenitor cells via regulation of cell cycle regulatory genes. Circ. Res. 92, 1049-1055 (2003).
16. Spyridopoulos I, Haendeler J, Urbich C et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 110, 3136-3142 (2004).
17. Dawn B, Guo YR, Rrzazadeh A et al. Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. Circ. Res. 98, 1098-1105 (2006).
18. Urbich C, Aicher A, Heeschen C et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J. Mol. Cell Cardiol. 39, 733-742 (2005).
19. Rehman J, Li J, Orschell CM et al. Peripheral blood 'endothelial progenitor cells' are derived from monocyte/macropbages and secrete anglogenic growth fiLctors. Circulation 107, 1164-1169 (2003).
20. Kinnaird T, Stabile E, Burnett MS et al. Bone marrow-derived cells for enhancing collateral development mechanisms, animal data, and initial clinical experiences. Circ. Res. 95, 354-363 (2004).
21. Deindl E, Zaruba MM, Brunner S et al. G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J. 20(7), 956-958 (2006).
22. Kuhlmann MT, Kirchhof P, Klocke R et al. G-CSF/SCF reduces inducible arthythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis. J. Exp. Med. 203(1), 879-887 (2006).
23. Buschmann IR, Hoefer IE, van Royen N et al. GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis 159, 343-356 (2001).
24. Seiler C, Pohl T, Wustmann K et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 23, 2012-2017 (2001).
25. Ziegelhoeffer T, Fernandez B, Kostin S et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ. Res. 94, 230-238 (2004).
26. Hattori K, Dias S, Heissig B et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 193, 1005-1014 (2001).
27. Silvestre JS, Mallat Z, Tedgui A et al. Post-ischaemic neovascularization and inflammation. Cardiovas. Res. 78(2), 242-249 (2008)
28. Harada. M, Qin Y, Takano H et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat. Med. 11, 305-311 (2005).
29. Takano H, Ueda K, Hasegawa H et al. G-CSF therapy for acute myocardial infarction. Trends Pharmacol. Sci. 28(10), 512-517 (2007).
30. Ueda K, Takano H, Hasegawa H et al. Granulocyte colony stimulating factor directly inhibits myocardial ischemia-reperfusion injury through Aktendothelial NO synthase pathway. Arterioscler. Thromb. Vasc. Biol. 26, e108-e113 (2006).
31. Sugano Y, Anzai T, Yoshikawa T et al. Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. Cardiovasc. Res. 65, 446-456 (2005).
32. Minatoguchi S, Takemura G, Chen XH et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 109, 2572-2580 (2004).
33. + cells in post-infarct cardiac repair mediated by G-CSE Cardio. Res. 71, 455-465 (2006).
34. Kang HJ, Kim HS, Koo BK et al. Intracoronary infusion of the mobilized peripheral blood stem cell by G-CSF is better than mobilization alone by G-CSF fbr improvement of cardiac function and remodeling: 2-year follow-up results of the Myocardial Regeneration and Angiogenesis in Myocardial Infarction with G-CSF and Intra-Coronary Stem Cell Infusion (MAGIC Cell) 1 trial. Am. Heart J. 153(2), 237e1-e8 (2007).
35. Suzuki K, Nagashima & Arai M et al. Effect of granulocyte colony-stimulating factor treatment at a low dose but for a long duration in patients with coronary heart disease. Circ. J. 70, 430-437 (2006).
36. Takano H, Hasegawa H, Kuwabara Y et al. Feasibility and safety of granulocyte colony-stimulating factor treatment in patients with acute myocardial infaction. Int. J. Candiol. 122(1), 41-47 (2007).
37. Valgimigli M, Rigolin GM, Cittaniti P et al. Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. Eur. Heart J. 26, 1838-1845 (2005).
38. Ellis SG, Penn MS, Bolwell B et al. Granulocyte colony stimulating factor in patients with large acute myocardial infarction: Results of a pilot dose-escalation randomized trial. Am. Heart J. 152, e91-e94 (2006).
39. Ince H, Petzsch M, Kleine HD et al. Preservation from left ventricular remodeling by Front-Integrated Revascularization And Stem Cell Liberation In Evolving Acute Myocardial Infarction By Use Of Granulocyte Colony-stimulating Factor (FIRSTLINE-AMI). Circulation 112(20), 3097-3106 (2005).
40. Ripa RS, Jørgensen E, Wang Y et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled Stem Cells in Myocardial Infarction (STEMMI) trial. Circulation 113(16), 1983-1992 (2006).
41. Zohlnhöfer D, Ott I, Mehilli J et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 295(9), 1003-1010 (2006).
42. Engelmann MG, Theiss HD, Hennig-Theiss C et al. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J. Am. Coll. Cardiol. 48(8), 1712-1721 (2006).
43. Leone AM, Galiuto L, Garramone B et al. Usefulness of granulocyte colony-stimulating factor in patients with a large anterior wall acute myocardial infarction to prevent left ventricular remodeling (the rigenera study). Am. J. Cardiol. 100(3), 3974-3903 (2007).
44. Lipinski MJ, Biondi-Zoccai GG, Abbate A et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J. Am. Coll. Cardiol. 50(18), 1761-1767 (2007).
45. Kang HJ, Lee HY, Na SH et al. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. Circulation 114(1 Suppl.), I145-I151 (2006).
46. Erbs S, Linke A, Adams V et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-cantrolled study. Circ. Res. 97, 756-762 (2005).
47. + stem cells for intractable angina: a Phase I/IIa double-blind, randomized controlled trial. Circulation 115(25), 3165-3172 (2007).
48. Kang WJ, Kang HJ, Kim HS et al. Tissue distribution of F-18 FDG labeled peripheral hematopoietic stem cell after intracoronary administration in patients with myocardial infarction. J. Nucl. Med. 47, 1295-1301 (2006).
49. Haghighat A, Weiss D, Whalin MK et al. Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor exacerbate atherosclerosis in apolipoprotein E-deficient mice. Circulation 115(15), 2049-2054 (2007).
50. Kang HJ, Kim YS, Koo BK et al. Effects of stem cell therapy with g-csf on coronary artery after drug-eluting stent implantation in patients with acute myocardial infarction. Heart 94(5), 604-609 (2007).
51. Cho HJ, Kim TY, Cho HJ et al. The effect of stem cell mobilization by granulocyte-colony stimulating factor on neointimal hyperplasia and endothelial heating after vascular injury with bare-metal versus paditaxel-eluting stents. J. Am. Coll. Cardiol. 48, 366-374 (2006).
52. Kang HJ, Kim HS, Zhang SY et al. Effects of intracoronary infiision of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infirction: the MAGIC cell randomised clinical trial. Lancet 363, 751-756 (2004).
53. Hasegawa H, Takano H, Ohtsuka M et al. G-CSF prevents the progression of atherosclerosis and neointimal formation in rabbits. Biochem. Biophys. Res. Commun. 344(1), 370-376 (2006).
54. Anagnostou A, Liu Z, Steiner M et al. Erythropoietin receptor mRNA expression in human endothefial cells. Proc. Natl Acad. Sci. USA 91, 3974-3978 (1994).
55. Tramontano AF, Muniyappa R, Black AD et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem. Biophys. Res. Commun. 308, 990-994 (2003).
56. Brines M, Grasso G, Fiordaliso F et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl Acad. Sci. USA 101, 14907-14912 (2004).
57. Anagnostou A, Lee ES, Kessimian N et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl Acad. Sci. USA 87, 5978-5982 (1990).
58. Ribatti D, Presta M, Vacca A et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93(8), 2627-2636 (1999).
59. Heeschen C, Aicher A, Lehmann R et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102, 1340-1346 (2003).
60. Coleman T, Westenfelder C, Togel F et al. Cytoprotective doses of erythropoietin or carbasnylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc. Natl Acad. Sci. USA 103(15), 5965-5970 (2006).
61. Bahlmann FH, De Groot K, Spandau JM et al. Erythropoietin regulates endothelial progenitor cells. Blood 103, 921-926 (2004).
62. Scholz D, Schaper W. Enhanced arteriogenesis in mice overexpressing erythropoietin. Cell Tissue Res. 324(3), 395-401 (2006).
63. Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305, 239-242 (2004).
64. Maiese K, Li F, Chong Z. New Avenues of Exploration for Erythropoietin. JAMA 293, 90-95 (2005).
65. Cai Z, Semenza G. Phosphatidylinositol-3-kinase signaling is required fbr erythropoietin-mediated acute protection against myocardial ischemia/ reperfusion injury. Circulation 109, 2050-2053 (2004).
66. Ratajczak J, Majka M, Mjowski J et al. Biological significance of MAPK, AKT and JAK-STAT protein activation by various erythro poietic factors in normal human early erythroid cells. Br. J. Haematol. 115, 195-204 (2001).
67. Brunet A, Bonni A, Zigmond MJ et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868 (1999).
68. Somervaille TC, Linch DC, Khwaja A. Growth factor withdrawal from primary human erythroid progenitors induces apoptosis through a pathway involving glycigen synthase kinase-3 and Bax, Blood 98, 1374-1381 (2001).
69. Chong ZZ, Kang JQ, Maiese K et al. Bcl-xL, cytochrome C, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J. Cereb. Blood Flow Metab. 23, 320-330 (2003).
70. Rui T, Feng Q, Lei M et al. Erythropoietin prevents die acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc. Res. 65, 719-727 (2005).
71. Wald M, Gumisky A, Borda E et al. Erythropoietin modified the cardiac action of ouabain in chronically anaemic-uraemic rats. Nephron 71, 190-196 (1995).
72. Porat O, Neumann D, Zamir O et al. Erythropoietin stimulates atrial natruiretic peptide secretion from adult rat cardiac atrium. J. Pharmacol. Exp. Ther. 276, 116-128 (1996).
73. Lipšic E, Schoemaker R, van der Meer P et al. Protective effects of erythropoietin in cardiac ischemia from bench to bedside. J. Am. Coll. Cardiol. 48, 216-217 (2006).
74. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. 6, 484-494 (2005).
75. Cabrillo I. Latini R, Kajstura J et al. Recombinant human erythropoietin protects die myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl Acad Sci. USA 100(8), 4802-4806 (2003).
76. Lipsic E, van der Meer P Henning RH et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J. Cardiovasc. Pharmacol. 44, 473-479 (2004).
77. Parsa CJ, Matsumoto A, Kim J et al. A novel protective effect of erythropoietin in the infarcted heart. J. Can. Invest. 112, 999-1007 (2003).
78. van der Meer P, Lipsic E, Henning RH et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J. Am. Coll. Cardiol. 46, 125-133 (2005).
79. Hirata A, Minamino T, Asanuma H et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Candiovasc. Drugs Ther. 19, 33-40 (2005).
80. McMahon LP, Mason K, Skinner SL et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol. Dial. Transplant 15, 142-150 (2000).
81. Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol. 37(7), 1775-1780 (2001).
82. Mancini DM, Katz SD, Lang CC et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107, 294-299 (2003).
83. Namiuchi S, Kagaya Y, Ohta J et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J. Am. Coll Cardiol. 45, 1406-1412 (2005).
84. van der Meer P, Voors AA, Lipsic E et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J. Am. Coll. Cardiol. 44, 636-637 (2004).
85. Ferrario M, Massa M, Rosti V et al. Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. Eur. Heart J. 1805-1813 (2007).
86. Lipsic E, van der Meer P, Voors AA et al. A single bolus of a long-acting erythropoietin analogue darbepoetin α in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc. Drugs Ther. 20, 135-141 (2006).
87. Akimoto T, Kusano E, Inaba T et al. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int. 58, 269-282 (2000).
88. 2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp. Hematol. 24, 392-397 (1996).
89. Heidenreich S, Rahn KH, Zidek W et al. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int. 39, 259-265 (1991).
90. Carlini R, Obialo CI. Rothstein M. Intravenous erythropoietin administration increases plasma endothelin and blood pressure in hemodialysis patients. Am. J. Hypertens. 6, 103-107 (1993).
91. Henry DH, Bowers P, Romano MT et al. Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch. Intern. Med. 164, 262-276 (2004).
92. Tobu M, Iqbal O, Fareed D et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin. Appl. Thromb. Hemost. 10, 225-232 (2004).
93. Stohlawetz PJ, Dzirlo L, Hergovich N et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95(9), 2983-2989 (2000).
94. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl. Cancer Inst. 98, 708-714 (2006).
95. Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369(9559), 381-388 (2007).
96. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299(8), 914-924 (2008).
97. Cotter DJ, Stefanik K, Zhang Y et al. Hematocrit was not validated as a surrogate end point fbr survival among epoetin-treated hemodialysis patients. J. Clin. Epidem. 57, 1086-1095 (2004).
98. Tang Y, Rinder H, Katz S et al. Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: Results of a double-blind, placebo-controlled randomized trial. Am. Heart J. 154(494) e14-e7 (2007).
99. Yasuda Y, Fujita Y, Matsuo T et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24, 1021-1029 (2003).
100. Henke M, Laszig R, Rübe C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362(9392), 1255-1260 (2003).
101. Erbayraktar S, Grasso G, Sfacteria A et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl Acad. Sci. USA 100, 6741-6746 (2003).
102. Fiordaliso F, Chimenti S, Staszewsky L et al. A nonerythropoietic derivative of erythropoietin protects the myocardium, from ischemia-reperfusion injury. Proc. Natl Acad. Sci. USA 102, 2046-2051 (2005).
103. Moon C, Krawczyk M, Paik D et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J. Pharmacol, Exp. Ther. 316, 999-1005 (2006).
104. Zhang D, Zhang F, Zhang Y et al. Combining erythropoietin infusion with intramyocardial delivery of bone marrow cells is more effective for cardiac repair. Transpl. Int. 20(2), 174-183 (2007).